A Phase 2 trial of a small molecule treatment for ulcerative colitis failed to meet its primary endpoint of clinical remission in patients due to an apparent treatment interference from corticosteroids, according to the developer Immunic Inc. The treatment, vidofludimus calcium, was being compared with placebo in patients with moderate-to-severe disease.
